HemaCare Corp. announced that it has expanded its capabilities to offer stem cell rich bone marrow products by increasing its donor recruitment efforts and internal collection capacity in the Los Angeles, California, area under the direct supervision of its Medical Director. HemaCares bone marrow portfolio, which includes unprocessed bone marrow, as well as highly purified isolated cell populations, is in high demand globally and a critical component in regenerative medicine research.

The focus of investigators who use bone marrow products include the study of how these cells can be programmed to treat degenerative diseases, for example diabetes and heart disease. When a particular stem cell derived from bone marrow can be programmed or induced to become a replacement for non-functioning cells, the promise of reinstating or regenerating cell function becomes possible.